Revenue
2019
2020
2021
2022
2023
2024
2025
Beam Therapeutics Inc. (BEAM)
Price—Loading quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $139.7M | $63.5M | $377.7M | $60.9M | $51.8M | $24,000 | $18,000 |
| Research & development | $409.6M | $367.6M | $437.4M | $311.6M | $387.1M | $103.2M | $54.6M |
| Operating expenses | $523.4M | $479.1M | $554.2M | $399.4M | $444.3M | $132.8M | $75.2M |
| Operating income | −$383.7M | −$415.6M | −$176.5M | −$338.5M | −$392.5M | −$132.8M | −$75.2M |
| EBITDAderived | −$361.4M | −$393.6M | −$156.5M | −$324.3M | −$385.0M | −$128.0M | −$71.7M |
| Net income | −$80.0M | −$376.7M | −$132.5M | −$289.1M | −$370.6M | −$194.6M | −$78.3M |
| Basic EPSper diluted share | -$0.81 | -$4.58 | -$1.72 | -$4.13 | -$5.77 | -$4.19 | -$14.05 |
| Diluted EPSper diluted share | -$0.81 | -$4.58 | -$1.72 | -$4.13 | -$5.77 | -$4.19 | -$14.05 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 26, 2026Form 4 | FMR LLCTenPercentOwner,Other | SellCommon Stock · indirect | 251.5K | $35.26 | $8.87M | 854.6K |
| Jun 25, 2026Form 4 | FMR LLCTenPercentOwner,Other | SellCommon Stock · indirect | 33.4K | $35.12 | $1.17M | 1.11M |
| Apr 1, 2026Form 4 · 10b5-1 | Evans John M.CEO | SellCommon Stock | 30.1K | $24.58 | $739.3K | 1.05M |
| Apr 1, 2026Form 4 · 10b5-1 | Simon AmyChief Medical Officer | SellCommon Stock | 6.7K | $24.58 | $164.7K | 102.7K |
| Apr 1, 2026Form 4 · 10b5-1 | Cavanagh Bethany JSVP, Finance and Treasurer | SellCommon Stock | 3.2K | $24.58 | $79.7K | 51.2K |